Stocksigma LogoStocksigma Logo

Gland Pharma Secures USFDA Approval for Generic Depo-Medrol Injectable Suspension

Gland Pharma received USFDA approval for its ANDA for Methylprednisolone Acetate Injectable Suspension USP across single-dose (40 mg/mL, 80 mg/mL) and

Gland Pharma Secures USFDA Approval for Generic Depo-Medrol Injectable Suspension

Gland Pharma Ltd 路 Press Release 路 03 Nov 2026, 5:01 pm

Gland Pharma Secures USFDA Approval for Generic Depo-Medrol Injectable Suspension Gland Pharma received USFDA approval for its ANDA for Methylprednisolone Acetate Injectable Suspension USP across single-dose (40 mg/mL, 80 mg/mL) and multiple-dose vials (200 mg/5 mL, 400 mg/10 mL, and 400 mg/5 mL). The product is bioequivalent and therapeutically equivalent to Pfizer's reference listed drug, Depo-Medrol Injectable Suspension, which treats various allergic, dermatologic, endocrine, and respiratory disorders. According to IQVIA data, Methylprednisolone injection generated US sales of approximately USD 214 million for the twelve months ending Aug'26.

Original exchange filing (PDF)

More announcements from Gland Pharma Ltd

All Gland Pharma Ltd announcements